a Department of Biology, Faculty of Sciences Semlalia, Laboratory of Biotechnology, Protection and Valorisation of Plant Resources (URAC35 association Unit) , Cadi Ayyad University , Marrakech , Morocco.
b Institut de Chimie Moléculaire de Reims, UMR CNRS 7312, SFR Cap-Santé FED 4231, UFR de Pharmacie , Université de Reims Champagne-Ardenne , Reims , France.
Pharm Biol. 2018 Dec;56(1):505-510. doi: 10.1080/13880209.2018.1499781.
Withania (Solanaceae) species are known to be a rich source of withanolides, which have shown several biological properties.
To identify the compounds responsible for Withania adpressa Coss. antioxidant activity and further test them for their NF-κB inhibition and antiproliferative activity in multiple myeloma cells.
Compounds were obtained from the EtOAc extract of W. adpressa leaves. Structure elucidation was carried out mainly by 1D- and 2D-NMR, and mass spectrometry. Isolated compounds were tested in a dose-response for their in vitro NF-κB inhibition and antiproliferative activity in multiple myeloma cells after 5 and 72 h treatment, respectively.
The fractionation resulted in the isolation of a new glycowithanolide named wadpressine (5) together with withanolide F, withaferin A, coagulin L, and nicotiflorin. The latter showed a moderate ability to scavenge free radicals in DPPH (IC = 35.3 µM) and NO (IC = 41.3 µM) assays. Withanolide F and withaferin A exhibited low µM antiproliferative activity against both multiple myeloma cancer stem cells and RPMI 8226 cells. Furthermore, they inhibited NF-κB activity with IC values of 1.2 and 0.047 µM, respectively. The other compounds showed a moderate inhibition of cell proliferation in RPMI 8226 cells, but were inactive against cancer stem cells and did not inhibit NF-κB activity.
One new glycowithanolide and four known compounds were isolated. Biological evaluation data gave further insight on the antitumor potential of withanolides for refractory cancers.
茄科植物(Solanaceae)被认为是丰富的生物来源,具有多种生物活性。
鉴定出与萎叶(Withania adpressa Coss.)抗氧化活性相关的化合物,并进一步测试它们对多发性骨髓瘤细胞中 NF-κB 抑制和抗增殖活性的影响。
从萎叶叶的乙酸乙酯提取物中获得化合物。结构鉴定主要通过 1D 和 2D-NMR 以及质谱完成。分离出的化合物在体外进行 NF-κB 抑制和多发性骨髓瘤细胞抗增殖活性的剂量反应测试,分别在 5 和 72 小时处理后进行。
分离得到一种新的糖基沃氏醇,命名为 wadpressine(5),以及沃氏醇 F、沃氏呋喃 A、凝固素 L 和烟碱甙。后者在 DPPH(IC=35.3µM)和 NO(IC=41.3µM)测定中显示出中等的自由基清除能力。沃氏醇 F 和沃氏呋喃 A 对多发性骨髓瘤癌干细胞和 RPMI 8226 细胞均表现出低µM 的抗增殖活性。此外,它们抑制 NF-κB 活性的 IC 值分别为 1.2 和 0.047µM。其他化合物在 RPMI 8226 细胞中表现出中等的细胞增殖抑制作用,但对癌干细胞无活性,也不抑制 NF-κB 活性。
分离出一种新的糖基沃氏醇和四种已知化合物。生物学评价数据进一步深入了解了沃氏醇对难治性癌症的抗肿瘤潜力。